PSORAS
MCID: PSR001
MIFTS: 63

Psoriatic Arthritis (PSORAS)

Categories: Bone diseases, Genetic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Psoriatic Arthritis

MalaCards integrated aliases for Psoriatic Arthritis:

Name: Psoriatic Arthritis 57 12 75 25 74 43 15 17
Psoriatic Arthritis, Susceptibility to 57 29 13 6
Arthropathic Psoriasis 12 25 33
Psoriatic Arthropathy 12 25 74
Arthritis, Psoriatic 44 72
Arthritis, Psoriatic, Susceptibility to 40
Psoriasis Arthropathica 74
Arthritis Psoriatica 12
Arthritic Psoriasis 74
Arthritis Psoriatic 55
Psoras 74

Classifications:



External Ids:

Disease Ontology 12 DOID:9008
OMIM 57 607507
ICD9CM 35 696.0
MeSH 44 D015535
NCIt 50 C61277
SNOMED-CT 68 33339001
ICD10 33 L40.5 L40.50
UMLS 72 C0003872

Summaries for Psoriatic Arthritis

Genetics Home Reference : 25 Psoriatic arthritis is a condition involving joint inflammation (arthritis) that usually occurs in combination with a skin disorder called psoriasis. Psoriasis is a chronic inflammatory condition characterized by patches of red, irritated skin that are often covered by flaky white scales. People with psoriasis may also have changes in their fingernails and toenails, such as nails that become pitted or ridged, crumble, or separate from the nail beds. Signs and symptoms of psoriatic arthritis include stiff, painful joints with redness, heat, and swelling in the surrounding tissues. When the hands and feet are affected, swelling and redness may result in a "sausage-like" appearance of the fingers or toes (dactylitis). In most people with psoriatic arthritis, psoriasis appears before joint problems develop. Psoriasis typically begins during adolescence or young adulthood, and psoriatic arthritis usually occurs between the ages of 30 and 50. However, both conditions may occur at any age. In a small number of cases, psoriatic arthritis develops in the absence of noticeable skin changes. Psoriatic arthritis may be difficult to distinguish from other forms of arthritis, particularly when skin changes are minimal or absent. Nail changes and dactylitis are two features that are characteristic of psoriatic arthritis, although they do not occur in all cases. Psoriatic arthritis is categorized into five types: distal interphalangeal predominant, asymmetric oligoarticular, symmetric polyarthritis, spondylitis, and arthritis mutilans. The distal interphalangeal predominant type affects mainly the ends of the fingers and toes. The distal interphalangeal joints are those closest to the nails. Nail changes are especially frequent with this form of psoriatic arthritis. The asymmetric oligoarticular and symmetric polyarthritis types are the most common forms of psoriatic arthritis. The asymmetric oligoarticular type of psoriatic arthritis involves different joints on each side of the body, while the symmetric polyarthritis form affects the same joints on each side. Any joint in the body may be affected in these forms of the disorder, and symptoms range from mild to severe. Some individuals with psoriatic arthritis have joint involvement that primarily involves spondylitis, which is inflammation in the joints between the vertebrae in the spine. Symptoms of this form of the disorder involve pain and stiffness in the back or neck, and movement is often impaired. Joints in the arms, legs, hands, and feet may also be involved. The most severe and least common type of psoriatic arthritis is called arthritis mutilans. Fewer than 5 percent of individuals with psoriatic arthritis have this form of the disorder. Arthritis mutilans involves severe inflammation that damages the joints in the hands and feet, resulting in deformation and movement problems. Bone loss (osteolysis) at the joints may lead to shortening (telescoping) of the fingers and toes. Neck and back pain may also occur.

MalaCards based summary : Psoriatic Arthritis, also known as psoriatic arthritis, susceptibility to, is related to spondyloarthropathy 1 and juvenile rheumatoid arthritis, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Psoriatic Arthritis is LTA (Lymphotoxin Alpha), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Tazarotene and Nicotinamide have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and t cells, and related phenotypes are growth/size/body region and cardiovascular system

Disease Ontology : 12 A syndrome that occurs in humans with psoriasis who also experience symptoms similar to arthritis.

OMIM : 57 Psoriasis (177900) is a chronic inflammatory skin disease that may have an autoimmune basis. The disorder has a strong but complex genetic basis, with a concordance rate of 50 to 70% among monozygotic twins. Psoriatic arthritis affects more than 10% of patients with psoriasis and, in most cases, there is an association between the severity of the arthritis and the skin involvement (Gudjonsson et al., 2002). (607507)

MedlinePlus : 43 Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.

UniProtKB/Swiss-Prot : 74 Psoriatic arthritis: An inflammatory, seronegative arthritis associated with psoriasis. It is a heterogeneous disorder ranging from a mild, non-destructive disease to a severe, progressive, erosive arthropathy. Five types of psoriatic arthritis have been defined: asymmetrical oligoarthritis characterized by primary involvement of the small joints of the fingers or toes; asymmetrical arthritis which involves the joints of the extremities; symmetrical polyarthritis characterized by a rheumatoid like pattern that can involve hands, wrists, ankles, and feet; arthritis mutilans, which is a rare but deforming and destructive condition; arthritis of the sacroiliac joints and spine (psoriatic spondylitis).

Wikipedia : 75 Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include... more...

Related Diseases for Psoriatic Arthritis

Diseases related to Psoriatic Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 632)
# Related Disease Score Top Affiliating Genes
1 spondyloarthropathy 1 33.9 TNFRSF1B TNFRSF11B TNF NOD2 MMP3 HLA-B
2 juvenile rheumatoid arthritis 33.2 TNFRSF1B TNF LTA IL1B HLA-DRB1 CRP
3 arthritis 32.6 TNFSF11 TNFRSF1B TNF PTPN22 NOD2 MMP3
4 uveitis 32.3 TNF NOD2 HLA-B
5 skin disease 32.1 TNF SELE IL13 HLA-C HLA-B
6 spondylarthropathy 32.0 TNF NOD2 LTA
7 spondylitis 32.0 TNFRSF1B TNF NOD2 MICA LTA HLA-C
8 spondyloarthropathy 32.0 TNFSF11 TNF MMP3 HLA-C HLA-B
9 tenosynovitis 31.9 TNFRSF1B CRP COMP
10 autoimmune disease 31.9 TNF PTPN22 IL1B HLA-DRB1
11 exanthem 31.8 TNFRSF1B TNF CRP
12 psoriasis 1 31.7 MICA HLA-C
13 osteoarthritis 31.7 TNF MMP3 IL1B COMP
14 reactive arthritis 31.7 TNF HLA-B CRP COMP
15 arthropathy 31.6 TNFSF11 TNFRSF11B TNF MICA CRP COMP
16 rheumatic disease 31.6 TNFRSF11B TNF IL1B HLA-DRB1 HLA-B CRP
17 inflammatory bowel disease 31.5 TNF NOD2 IL1B IL13 CRP
18 crohn's colitis 31.5 TNF NOD2 IL1B
19 atherosclerosis susceptibility 31.4 TNF SELE CRP
20 ulcerative colitis 31.4 TNF NOD2 IL1B CRP
21 pericarditis 31.4 TNF IL1B CRP
22 osteomyelitis 31.2 TNFSF11 TNF IL1B
23 acquired immunodeficiency syndrome 31.2 TNF IL1B HLA-B
24 meningitis 31.1 TNF IL1B CRP
25 gastroenteritis 31.1 TNF IL1B CRP
26 complex regional pain syndrome 31.1 TNF IL1B HLA-B
27 vasculitis 31.1 TNFRSF1B TNF SELE HLA-B CRP
28 leishmaniasis 31.1 TNF IL1B IL13 HLA-DRB1
29 oligoarticular juvenile idiopathic arthritis 31.1 TNF PTPN22 HLA-DRB1
30 pharyngitis 31.1 IL1B HLA-DRB1 CRP
31 synovitis 31.0 TNFSF11 TNFRSF11B TNF SELE MMP3 IL1B
32 stevens-johnson syndrome/toxic epidermal necrolysis 31.0 IL13 HLA-C HLA-B
33 cholangitis 31.0 TNF HLA-DRB1 HLA-B CRP
34 histoplasmosis 31.0 MICA HLA-DRB1 HLA-B
35 pneumonia 31.0 TNF IL1B IL13 CRP
36 bone disease 30.9 TNFSF11 TNFRSF11B TNF IL1B
37 gastrointestinal system disease 30.9 TNF NOD2 IL1B CRP
38 proteasome-associated autoinflammatory syndrome 1 30.9 TNF SELE IL1B IL13 CRP
39 optic neuritis 30.9 TNF LTA HLA-DRB1
40 temporal arteritis 30.9 TNF PTPN22 HLA-DRB1 CRP
41 tonsillitis 30.9 TNF LTA IL1B
42 adult-onset still's disease 30.9 TNF IL1B CRP
43 melkersson-rosenthal syndrome 30.9 TNFRSF1B TNF NOD2
44 guttate psoriasis 30.9 NOD2 HLA-C
45 bronchiolitis 30.9 TNF IL13 CRP
46 arteries, anomalies of 30.9 TNF SELE IL1B CRP
47 rubella 30.8 TNF HLA-DRB1 HLA-B
48 lyme disease 30.8 TNF IL1B CRP
49 sclerosing cholangitis 30.8 TNF HLA-DRB1 HLA-C HLA-B
50 lymphadenitis 30.8 TNF NOD2 IL1B

Graphical network of the top 20 diseases related to Psoriatic Arthritis:



Diseases related to Psoriatic Arthritis

Symptoms & Phenotypes for Psoriatic Arthritis

Clinical features from OMIM:

607507

UMLS symptoms related to Psoriatic Arthritis:


back pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Psoriatic Arthritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.15 COMP IL13 IL1B LTA NOD2 PTPN22
2 cardiovascular system MP:0005385 10.1 COMP CRP IL1B LTA PTPN22 SELE
3 hematopoietic system MP:0005397 10.1 IL13 IL1B LTA MMP3 NOD2 PTPN22
4 homeostasis/metabolism MP:0005376 10.07 COMP CRP IL13 IL1B LTA MMP3
5 immune system MP:0005387 10 COMP CRP IL13 IL1B LTA MMP3
6 respiratory system MP:0005388 9.5 IL13 LTA PTPN22 SELE TNF TNFRSF1B
7 skeleton MP:0005390 9.32 COMP IL13 IL1B LTA MMP3 NOD2

Drugs & Therapeutics for Psoriatic Arthritis

Drugs for Psoriatic Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 176)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
2
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Etanercept Approved, Investigational Phase 4 185243-69-0
5
Adalimumab Approved Phase 4 331731-18-1 16219006
6
Certolizumab pegol Approved Phase 4 428863-50-7
7
Infliximab Approved Phase 4 170277-31-3
8
tannic acid Approved Phase 4 1401-55-4
9
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
10
Atorvastatin Approved Phase 4 134523-00-5 60823
11
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
12
carbamide peroxide Approved Phase 4 124-43-6
13 Ixekizumab Approved, Investigational Phase 4 1143503-69-8
14
Tofacitinib Approved, Investigational Phase 4 477600-75-2
15
Sulfasalazine Approved Phase 4 599-79-1 5359476 5353980
16
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
17
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
18
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
19
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
20
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
21
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
22
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
23
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
24 Micronutrients Phase 4
25 Trace Elements Phase 4
26 Vitamins Phase 4
27 Nutrients Phase 4
28 Vitamin B3 Phase 4
29 Keratolytic Agents Phase 4
30 Nicotinic Acids Phase 4
31 Central Nervous System Depressants Phase 4
32 Anesthetics Phase 4
33 Anti-Arrhythmia Agents Phase 4
34 Anesthetics, Local Phase 4
35 Sodium Channel Blockers Phase 4
36 insulin Phase 4
37 Insulin, Globin Zinc Phase 4
38 Diuretics, Potassium Sparing Phase 4
39 Chlorhexidine gluconate Phase 4
40 Vasoconstrictor Agents Phase 4
41 Antibodies Phase 4
42 Immunoglobulins Phase 4
43 Antibodies, Monoclonal Phase 4
44 Adrenocorticotropic Hormone Phase 4
45 Melanocyte-Stimulating Hormones Phase 4
46 beta-endorphin Phase 4
47 Lipid Regulating Agents Phase 4
48 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
49 Hypolipidemic Agents Phase 4
50 Anticholesteremic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 393)
# Name Status NCT ID Phase Drugs
1 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
2 Title of Study: A Single-Site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection) an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Psoriatic Arthritis (PsA) Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
3 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
4 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
5 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
6 Rating Evaluations in Psoriatic Arthritis (PsA) With Enbrel® Completed NCT00127842 Phase 4 Etanercept
7 A Randomized, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects With Psoriatic Arthritis. Completed NCT00245960 Phase 4 etanercept
8 Enbrel® in Psoriatic Arthritis Completed NCT00111124 Phase 4 Enbrel®
9 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
10 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice Completed NCT01147874 Phase 4
11 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis After 16 Weeks of Treatment Compared to Placebo and to Assess the Safety, Tolerability and Efficacy up to 52 Weeks Completed NCT02798211 Phase 4 Secukinumab;Secukinumab
12 TNF-α Blockade for Psoriatic Arthritis - A Clinical and MRI Study, and the Effects on Cytokine and Cardiovascular Risk Profile Completed NCT00432406 Phase 4 Infliximab;Etanercept
13 Can New Imaging- and Biomarkers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Psoriatic Arthritis Patients Receiving Adalimumab? Completed NCT01465438 Phase 4 Adalimumab
14 Microarray Analysis of Peripheral Blood and Tissues of Patients With Immune Mediated Inflammatory Diseases Completed NCT00462072 Phase 4 Infliximab
15 A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy Completed NCT00161655 Phase 4 Etanercept;Methotrexate
16 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
17 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
18 Effectiveness of Triamcinolone Hexacetonide Intra-articular Injection in Interphalangeal Joints: a 12 Weeks Randomized Controlled Trial in Osteoarthritis Hand Patients Completed NCT02102620 Phase 4 Intra-articular injection with corticosteroid;Intra-articular injection with lidocaine
19 A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or = 1 Conventional Synthetic DMARD Recruiting NCT03747939 Phase 4 Apremilast (CC-10004)
20 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Recruiting NCT03733925 Phase 4 Golimumab
21 A PHASE 4, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMPACT OF APREMILAST (CC-10004) MONOTHERAPY ON MRI OUTCOMES IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS Recruiting NCT03783026 Phase 4 CC-10004
22 Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS) Recruiting NCT03419650 Phase 4 ACTHar
23 An Open-label Pilot Study to Investigate the Efficacy of Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Recruiting NCT03521687 Phase 4 Apremilast
24 A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis Recruiting NCT03082729 Phase 4 Apremilast
25 Subclinical Cardiovascular Disease in Psoriatic Disease Recruiting NCT03228017 Phase 4 Aspirin and/or Atorvastatin
26 GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC). Recruiting NCT02687724 Phase 4 Golimumab (GLM)
27 Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis Recruiting NCT03445845 Phase 4 Secukinumab;TNF blocker
28 Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis Recruiting NCT02829424 Phase 4 Methotrexate;Methotrexate Placebo
29 A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive Active, not recruiting NCT03151551 Phase 4 Ixekizumab;Adalimumab
30 A Phase 4 Open-label Randomized Controlled Study COmparing the Effectiveness of Adalimumab iNTROduction and Methotrexate Dose escaLation in Subjects With Psoriatic Arthritis (CONTROL) Active, not recruiting NCT02814175 Phase 4 methotrexate (MTX)
31 Pilot Study of the Safety and Efficacy of Quadrivalent Human Papillomavirus Vaccine (Gardasil®) in Female Subjects With Juvenile Idiopathic Arthritis (JIA)/ Seronegative Arthritis Active, not recruiting NCT00573651 Phase 4
32 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Active, not recruiting NCT02477150 Phase 4
33 An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis Enrolling by invitation NCT03022617 Phase 4 Apremilast
34 Efficacy of Tofacitinib in Reduction of Inflammation Detected on MRI in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement - a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Not yet recruiting NCT04062695 Phase 4 Tofacitinib 5 MG Oral Tablet [Xeljanz];Placebo oral tablet
35 Prevention of Metacarpophalangeal Joints Structure Damage in Patients With Psoriatic Arthritis Using Secukinumab Not yet recruiting NCT03623867 Phase 4 Secukinumab;Placebo
36 Clinical Effectiveness of Symptomatic Therapy Compared to Standard Step up Care for the Treatment of Low Impact Psoriatic Oligoarthritis: a 2 Arm Parallel Group Feasibility Study Not yet recruiting NCT03797872 Phase 4 Methotrexate;Sulfasalazine;Leflunomide;Methylprednisolone;Triamcinolone
37 Clinical Effectiveness of Standard Step up Care (Methotrexate) Compared to Early Combination DMARD Therapy With Standard Step up Care Compared to Early Use of TNF Inhibitors With Standard Step up Care for the Treatment of Moderate to Severe Psoriatic Arthritis: a 3-arm Parallel Group Randomised Controlled Trial. Not yet recruiting NCT03739853 Phase 4 Methotrexate;Sulfasalazine;Leflunomide;Adalimumab
38 An Open-label, Single-Arm Pilot Study Investigating the Efficacy and Safety of Apremilast for the Treatment of Moderate to Severe Chronic Hand Dermatitis Not yet recruiting NCT03741933 Phase 4 Apremilast 30mg
39 A Skin and Synovial Tissue Assessment of Overlapping Genes and Their Response After 3 Months Treatment With Apremilast in Patients With Psoriatic Arthritis Withdrawn NCT02558361 Phase 4 Treatment with Apremilast
40 Methotrexate in the Treatment of Axial Spondyloarthritis. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study. Withdrawn NCT00298012 Phase 4 Methotrexate
41 Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis Unknown status NCT03191539 Phase 3 Apremilast
42 A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Safety and Efficacy Study of Recombinant Human TNF Receptor-IgG Fusion Protein for Injection (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis Unknown status NCT02701205 Phase 3 placebo
43 A Multi-Center Continuation Trial for Patients Completing Study M02-518 and M02-570 of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Moderate to Severely Active Psoriatic Arthritis Completed NCT00195689 Phase 3
44 Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Adult-Onset Active and Progressive Psoriatic Arthritis (PsA) Completed NCT01087788 Phase 3
45 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Psoriatic Arthritis Completed NCT01392326 Phase 3 Secukinumab (75 mg);Secukinumab (150 mg);Placebo Comparator
46 Safety and Efficacy of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) - An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Standard Therapy, Including Patients Who Failed Prior Treatment With Other TNF-Inhibitors (STEREO) Completed NCT00235885 Phase 3 adalimumab
47 A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis Completed NCT01695239 Phase 3 Ixekizumab;Placebo;Adalimumab
48 A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM) Completed NCT00427362 Phase 3 Adalimumab
49 A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis Completed NCT02349295 Phase 3 Placebo;Ixekizumab 80 mg Q4W;Ixekizumab 80 mg Q2W
50 A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis Completed NCT02584855 Phase 3 Ixekizumab;Placebo

Search NIH Clinical Center for Psoriatic Arthritis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Adalimumab
Apremilast
Auranofin
Aurothioglucose
Betamethasone
Bupivacaine
Certolizumab pegol
Corticotropin
Cortisone acetate
Etanercept
Etanercept
Golimumab
Hydrocortisone
Infliximab
Prednisolone
Prednisone
Secukinumab
Sodium aurothiomalate
Tetracosactide
Triamcinolone
Ustekinumab

Cochrane evidence based reviews: arthritis, psoriatic

Genetic Tests for Psoriatic Arthritis

Genetic tests related to Psoriatic Arthritis:

# Genetic test Affiliating Genes
1 Psoriatic Arthritis, Susceptibility to 29 LTA NOD2

Anatomical Context for Psoriatic Arthritis

MalaCards organs/tissues related to Psoriatic Arthritis:

41
Skin, Bone, T Cells, Testes, Endothelial, Liver, Monocytes

Publications for Psoriatic Arthritis

Articles related to Psoriatic Arthritis:

(show top 50) (show all 8055)
# Title Authors PMID Year
1
Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. 38 8 71
12746914 2003
2
CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. 9 38 8
12879366 2003
3
Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. 9 38 8
12639988 2003
4
Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. 38 8
18800148 2009
5
PSORS2 markers are not associated with psoriatic arthritis in the Italian population. 38 8
16733365 2006
6
A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. 38 8
12474146 2003
7
HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. 38 8
11841557 2002
8
HLA-C locus alleles in patients with psoriatic arthritis (PsA). 38 8
10321964 1999
9
Maternal and infant pregnancy outcomes in women with psoriatic arthritis: a Swedish nationwide cohort study. 38 17
31188526 2019
10
Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. 38 17
30700196 2019
11
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study. 38 17
30681555 2019
12
The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. 38 88
20500689 2010
13
Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. 71
16418737 2006
14
An association between asthma and TNF-308G/A polymorphism: meta-analysis. 71
16865291 2006
15
Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. 71
14681301 2004
16
Association between the tumor necrosis factor-alpha -308 G/A gene polymorphism and migraine. 71
14718719 2004
17
Association between G-308A polymorphism of the tumor necrosis factor-alpha gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents. 71
12485196 2002
18
Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. 71
12426569 2002
19
Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease. 71
11826025 2002
20
Relation between tumour necrosis factor polymorphism TNFalpha-308 and risk of asthma. 71
11896460 2002
21
Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. 71
11506397 2001
22
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. 71
11261930 2001
23
Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. 71
10450718 1999
24
Genetic contribution of the tumor necrosis factor region in Guillain-Barré syndrome. 71
9818939 1998
25
Significantly earlier age at onset for the HLA-Cw6-positive than for the Cw6-negative psoriatic sibling. 8
9347803 1997
26
Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor alpha with human IDDM. 71
8056188 1994
27
Lipoma arborescens co-existing with psoriatic arthritis releases tumour necrosis factor alpha and matrix metalloproteinase 3. 9 38
20237127 2010
28
Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. 9 38
20415816 2010
29
Infliximab and anterior optic neuropathy: case report and review of the literature. 9 38
19916016 2010
30
The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project. 9 38
19904485 2010
31
Possible association between NOD2 variants and joint surgery in psoriatic arthritis. 9 38
20346235 2010
32
A case of tuberculous arthritis following the use of etanercept. 9 38
19949742 2009
33
Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. 9 38
19554022 2009
34
Psoriatic arthritis: pharmacoeconomic considerations. 9 38
19691929 2009
35
Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? 9 38
19479708 2009
36
Spondyloarthropathies: Targeted therapy for psoriatic arthritis. 9 38
19412187 2009
37
Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. 9 38
19188093 2009
38
Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. 9 38
19505409 2009
39
Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy. 9 38
19363860 2009
40
Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another? 9 38
19151120 2009
41
Leukemic phase of follicular lymphoma after treatment with etanercept in a patient with psoriasis. 9 38
19222252 2009
42
Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. 9 38
19016693 2009
43
Generalized pustulosis induced by adalimumab in a patient with rheumatoid arthritis - a therapeutic challenge. 9 38
18986481 2008
44
Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. 9 38
19036225 2008
45
Etanercept in therapy multiresistant overlapping pityriasis lichenoides. 9 38
19112768 2008
46
Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. 9 38
18694376 2008
47
Spinal epidural abscess associated with infliximab treatment for psoriatic arthritis. Case report. 9 38
18928222 2008
48
Genome-wide association scan in psoriasis: new insights into chronic inflammatory disease. 9 38
20476959 2008
49
[First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept]. 9 38
18210001 2008
50
Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. 9 38
18503600 2008

Variations for Psoriatic Arthritis

ClinVar genetic disease variations for Psoriatic Arthritis:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TNF TNF, -308G-A single nucleotide variant risk factor
2 LTA NM_001159740.2(LTA): c.-9-198A> G single nucleotide variant risk factor rs909253 6:31540313-31540313 6:31572536-31572536
3 NOD2 NM_022162.3(NOD2): c.2863G> A (p.Val955Ile) single nucleotide variant Benign/Likely benign rs5743291 16:50757276-50757276 16:50723365-50723365

Expression for Psoriatic Arthritis

Search GEO for disease gene expression data for Psoriatic Arthritis.

Pathways for Psoriatic Arthritis

Pathways related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.65 TNFSF11 TNFRSF1B TNFRSF11B TNF PTPN22 NOD2
2
Show member pathways
13.27 TNFSF11 TNFRSF1B TNF PTPN22 LTA IL1B
3
Show member pathways
12.93 TNFSF11 TNFRSF1B TNFRSF11B TNF SELE LTA
4
Show member pathways
12.93 TNFRSF1B TNF MICA IL1B HLA-C HLA-B
5
Show member pathways
12.84 TNFSF11 TNFRSF1B TNFRSF11B TNF NOD2 MMP3
6
Show member pathways
12.65 TNFRSF1B TNF MICA LTA IL1B IL13
7
Show member pathways
12.57 TNF NOD2 IL1B IL13 HLA-DRB1
8 12.53 TNIP1 TNFSF11 TNFRSF1B TNF PTPN22 IL1B
9
Show member pathways
12.51 TNIP1 TNFSF11 TNFRSF1B TNFRSF11B TNF LTA
10 12.34 TNF LTA HLA-DRB1 HLA-C HLA-B
11
Show member pathways
12.3 TNF MMP3 IL1B IL13
12
Show member pathways
12.24 TNF LTA IL1B IL13 HLA-C HLA-B
13 12.2 TNF NOD2 IL1B HLA-DRB1
14 12.12 HLA-DRB1 HLA-C HLA-B COMP
15 12.09 SELE HLA-DRB1 HLA-C HLA-B CD58
16 12.03 TNFSF11 TNFRSF11B TNF IL1B
17
Show member pathways
12.01 TNF MMP3 IL1B IL13
18 11.91 TNFRSF1B TNF MMP3 IL1B IL13
19 11.9 TNFSF11 TNF LTA IL1B
20 11.86 TNF SELE IL1B
21 11.84 TNF IL1B HLA-DRB1
22 11.79 TNF LTA IL1B IL13
23 11.73 TNFSF11 TNF MMP3 IL1B HLA-DRB1
24 11.72 TNF MMP3 IL1B IL13
25
Show member pathways
11.71 TNFSF11 TNFRSF1B TNF
26
Show member pathways
11.65 TNF SELE MMP3 IL1B
27 11.63 TNF IL1B IL13
28 11.56 TNFRSF1B TNF LTA
29
Show member pathways
11.52 TNFRSF1B TNF LTA
30 11.5 TNF SELE IL1B COMP
31 11.49 TNFRSF1B TNF IL1B IL13
32
Show member pathways
11.44 TNFRSF11B TNF IL1B
33 11.43 TNFSF11 TNFRSF11B TNF IL1B
34 11.37 TNF SELE IL1B
35 11.29 TNF IL1B IL13
36 11.22 TNFRSF1B TNF SELE NOD2 MMP3 LTA
37 11.2 TNFSF11 TNF LTA IL1B IL13
38 11.18 TNFSF11 TNFRSF1B TNFRSF11B LTA
39 11.09 TNF IL1B IL13 HLA-DRB1
40 10.98 TNFSF11 TNF LTA IL1B IL13
41 10.82 TNFSF11 TNFRSF11B

GO Terms for Psoriatic Arthritis

Cellular components related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.96 TNFSF11 TNFRSF1B TNFRSF11B TNF MMP3 LTA
2 secretory granule membrane GO:0030667 9.58 HLA-C HLA-B CD58
3 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-DRB1 HLA-C HLA-B
4 cell surface GO:0009986 9.5 TNF NOD2 MICA HLA-DRB1 HLA-C HLA-B
5 extracellular space GO:0005615 9.4 TNFSF11 TNFRSF11B TNF SELE MMP3 MIR146A
6 MHC class I protein complex GO:0042612 9.37 HLA-C HLA-B
7 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.33 HLA-DRB1 HLA-C HLA-B

Biological processes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.95 TNF SELE IL1B CD58
2 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.92 TNFSF11 TNF NOD2 IL1B
3 cellular response to lipopolysaccharide GO:0071222 9.91 TNFRSF1B TNF NOD2 IL1B
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 TNFSF11 TNF NOD2 IL1B
5 positive regulation of gene expression GO:0010628 9.87 TNFSF11 TNF PTPN22 MIR146A IL1B IL13
6 defense response to Gram-positive bacterium GO:0050830 9.86 TNF LTA CRP
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.86 TNF PTPN22 NOD2
8 response to nutrient GO:0007584 9.85 TNFRSF11B NOD2 LTA
9 cytokine-mediated signaling pathway GO:0019221 9.85 TNFSF11 TNFRSF1B TNF MMP3 IL1B IL13
10 interferon-gamma-mediated signaling pathway GO:0060333 9.84 HLA-DRB1 HLA-C HLA-B
11 cellular response to organic cyclic compound GO:0071407 9.83 TNF NOD2 IL1B
12 positive regulation of MAP kinase activity GO:0043406 9.83 TNFSF11 TNF NOD2
13 positive regulation of interleukin-6 production GO:0032755 9.81 TNF NOD2 IL1B
14 inflammatory response GO:0006954 9.8 TNIP1 TNFRSF1B TNF SELE IL1B IL13
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.79 TNF NOD2 IL1B
16 positive regulation of JNK cascade GO:0046330 9.78 TNFSF11 TNF NOD2 IL1B
17 positive regulation of interferon-gamma production GO:0032729 9.77 TNF LTA IL1B
18 antigen processing and presentation GO:0019882 9.76 HLA-DRB1 HLA-C HLA-B
19 lipopolysaccharide-mediated signaling pathway GO:0031663 9.72 TNF PTPN22 IL1B
20 regulation of inflammatory response GO:0050727 9.71 TNIP1 TNF SELE NOD2
21 regulation of osteoclast differentiation GO:0045670 9.69 TNFSF11 TNF
22 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.69 TNF IL1B
23 negative regulation of growth of symbiont in host GO:0044130 9.69 TNF LTA
24 positive regulation of interleukin-8 production GO:0032757 9.69 TNF NOD2 IL1B
25 negative regulation of lipid storage GO:0010888 9.68 TNF CRP
26 detection of bacterium GO:0016045 9.67 NOD2 HLA-DRB1
27 cellular response to muramyl dipeptide GO:0071225 9.67 PTPN22 NOD2
28 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.67 HLA-C HLA-B
29 positive regulation of chemokine biosynthetic process GO:0045080 9.65 TNF IL1B
30 regulation of establishment of endothelial barrier GO:1903140 9.64 TNF IL1B
31 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.64 HLA-C HLA-B
32 positive regulation of neuroinflammatory response GO:0150078 9.63 TNF IL1B
33 positive regulation of glial cell proliferation GO:0060252 9.63 TNF LTA IL1B
34 response to lipopolysaccharide GO:0032496 9.63 TNFRSF1B SELE PTPN22 LTA IL1B IL13
35 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.61 TNF LTA
36 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.61 TNFRSF1B TNF IL1B
37 positive regulation of fever generation GO:0031622 9.6 TNF IL1B
38 sequestering of triglyceride GO:0030730 9.57 TNF IL1B
39 positive regulation of protein K63-linked ubiquitination GO:1902523 9.54 PTPN22 NOD2
40 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.52 TNF IL1B
41 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.49 TNF LTA
42 tumor necrosis factor-mediated signaling pathway GO:0033209 9.35 TNFSF11 TNFRSF1B TNFRSF11B TNF LTA
43 immune response GO:0006955 9.32 TNFSF11 TNFRSF1B TNF MICA LTA IL1B
44 chronic inflammatory response to antigenic stimulus GO:0002439 9.26 TNF

Molecular functions related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.33 HLA-DRB1 HLA-C HLA-B
2 tumor necrosis factor receptor binding GO:0005164 9.13 TNFSF11 TNF LTA
3 cytokine activity GO:0005125 9.1 TNFSF11 TNFRSF11B TNF LTA IL1B IL13
4 protein binding GO:0005515 10.19 TNIP1 TNFSF11 TNFRSF1B TNFRSF11B TNF SELE

Sources for Psoriatic Arthritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....